Project Grant R21AI190982
Award Date
7/23/25
Completion Date
6/30/27
Dollars Obligated
$556K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $438,038 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, Berkeley to conduct research on the regulation of infectious spore formation in the fungal pathogen Coccidioides posadasii. The project aims to use experimental and computational genomic approaches to study how Coccidioides, the causative agent of Valley Fever, preferentially...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on exploring the genetic basis of two pathogenesis-relevant traits in the Cryptococcus fungal genus: thermotolerance and azole drug resistance. The $443,944 award, with a performance period from August 2024 to July 2029, will employ high-throughput genetic approaches to characterize genome-wide...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, has awarded a $300,156 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Intact Genomics Inc., a minority-owned small business. The funding will support research to identify new antifungal compounds with novel mechanisms of action from filamentous fungi. The key objectives are to demonstrate the use of Aspergillus nidulans as a...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,205,213 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The grant, titled "Deciphering Immunopathogenesis of Mucormycosis to Advance Risk Stratification, Diagnosis and Management of the Disease", aims to improve understanding of the immune response and pathogenesis of mucormycosis, a...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $494,696 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Texas Health Science Center at San Antonio (UTHSCSA). The grant will fund research to better understand the translational control mechanisms that allow the fungal pathogen Candida albicans to respond to host environmental stresses and undergo critical morphological changes that enable infection....
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $249,749 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Iowa. The grant supports research to develop a new approach for analyzing the transcriptional control of virulence in the fungal pathogen Aspergillus fumigatus, a leading cause of life-threatening infections in immunocompromised patients. The research aims to express a nanobody-E3 ligase fusion protein...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $857,215 to HMH Hospitals Corporation (doing business as Hackensack University Medical Center) to conduct research on how the fungal pathogen Candida albicans adapts to different host environments, such as the oral and systemic infection niches. The research aims to decipher how the fungal acetylome, regulated by the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a $170,000 research project by Prokaryotics Incorporated to develop novel antifungal therapeutics. The goal is to perform structural biology studies on the GPI ethanolamine phosphate transferase enzyme MCD4, which is a promising target for new antifungal drug candidates. The research aims to obtain...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $483,194 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Research Institute at Nationwide Children's Hospital. The grant, with a project period from March 2025 to February 2030, aims to define the protective CD4+ T cell response that supports effective CD8+ T cell immunity against the Hepatitis C Virus (HCV). The research will leverage historical blood and liver samples...
This Project Grant award of $1,454,386.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports fundamental research to better understand the epigenetic regulation of the HIV-1 viral RNA cap. The research aims to define the structural basis of HIV cap hypermethylation and its linkage to modulating host innate immune signaling, with the goal of developing new treatments to neutralize deleterious...